AIM
RDY icon

Aikya Investment Management’s Dr. Reddy's Laboratories RDY Stock Holding History

Aikya Investment Management’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$123M Buy
8,493,852
+494,056
+6% +$6.67M 36.13% 1
2026
Q1 		$111M Buy
7,999,796
+661,271
+9% +$9.21M 32.14% 2
2025
Q4 		$103M Buy
7,338,525
+623,518
+9% +$8.75M 23.37% 3
2025
Q3 		$93.9M Buy
6,715,007
+360,028
+6% +$5.18M 26.28% 3
2025
Q2 		$95.5M Buy
6,354,979
+154,604
+2% +$2.21M 28.64% 2
2025
Q1 		$81.8M Buy
6,200,375
+589,872
+11% +$8.14M 30.32% 2
2024
Q4 		$88.6M Buy
5,610,503
+174,503
+3% +$2.62M 36.88% 2
2024
Q3 		$17.3M Sell
5,436,000
-1,508,965
-22% -$24.3M 9.6% 3
2024
Q2 		$106M Buy
6,944,965
+745,290
+12% +$10.7M 30.55% 2
2024
Q1 		$90.9M Buy
6,199,675
+716,810
+13% +$10.5M 33.3% 2
2023
Q4 		$75.8M Buy
+5,482,865
New +$73.3M 33.82% 2

Other funds holding RDY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Aikya Investment Management's RDY Position: Q2 2026 in Review

Aikya Investment Management increased its Dr. Reddy's Laboratories (RDY) stake by 6.2% in Q2 2026, buying an estimated $6.67M and bringing the position to 8,493,852 shares worth $123M. The position accounts for 36.13% of the portfolio, ranked #1.

Aikya Investment Management first reported a position in RDY in Q4 2023 and has held it in 11 quarters since. 238 funds tracked by Wall St. Rank hold RDY as of Q2 2026.

  • Aikya Investment Management held 8,493,852 shares of Dr. Reddy's Laboratories worth $123M as of Q2 2026.
  • Aikya Investment Management bought 494,056 Dr. Reddy's Laboratories shares in Q2 2026, an estimated $6.67M.
  • Dr. Reddy's Laboratories made up 36.13% of Aikya Investment Management's portfolio in Q2 2026, its #1 holding.
  • Aikya Investment Management first reported a position in Dr. Reddy's Laboratories in Q4 2023 and has held it in 11 quarters since.
  • 238 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2026.

Based on Aikya Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.